The drug, when combined with existing drug bortezomib plus steroid dexamethasone, significantly extended the time before the disease progressed, or the patients died, in those suffering from relapsed or refractory multiple myeloma - the third most common type of blood cancer which is considered difficult to treat.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment